Literature DB >> 7675360

Cytotoxicity of 213Bi- and 225Ac-immunoconjugates.

F M Kaspersen1, E Bos, A V Doornmalen, M W Geerlings, C Apostolidis, R Molinet.   

Abstract

This paper describes in vitro cytotoxicity experiments with 213Bi- and 225Ac-immunoconjugates on the human epidermoid tumour cell line A431 using a blood group A-reactive murine IgG (2D11) as the specific antibody and MOPC 21 as the control antibody. With both radionuclides, specific cell-killing was achieved. The observed cytotoxicity of 213Bi (T1/2 - 47 min) indicates that this radionuclide is a useful alternative for the alpha-emitter 212Bi in the treatment of blood-borne malignancies. 225Ac-immunoconjugates (T1/2 of 225Ac is 10 days) may be applicable for the treatment of solid tumours, since the daughter radionuclides of 225Ac contribute to the cytotoxic efficacy by a field effect (i.e. toxicity in an area distal from the antibody-binding site). The lack of an adequate chelator for 225Ac is a major drawback.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7675360     DOI: 10.1097/00006231-199506000-00009

Source DB:  PubMed          Journal:  Nucl Med Commun        ISSN: 0143-3636            Impact factor:   1.690


  6 in total

1.  In vitro evaluation of 213Bi-rituximab versus external gamma irradiation for the treatment of B-CLL patients: relative biological efficacy with respect to apoptosis induction and chromosomal damage.

Authors:  Katia Vandenbulcke; Filip De Vos; Fritz Offner; Jan Philippé; Christos Apostolidis; Roger Molinet; Tuomo K Nikula; Klaus Bacher; Virginie de Gelder; Anne Vral; Christophe Lahorte; Hubert Thierens; Rudi A Dierckx; Guido Slegers
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-07-03       Impact factor: 9.236

Review 2.  Actinium-225 in targeted alpha-particle therapeutic applications.

Authors:  David A Scheinberg; Michael R McDevitt
Journal:  Curr Radiopharm       Date:  2011-10

Review 3.  Alpha-Emitters and Targeted Alpha Therapy in Oncology: from Basic Science to Clinical Investigations.

Authors:  Mehran Makvandi; Edouard Dupis; Jonathan W Engle; F Meiring Nortier; Michael E Fassbender; Sam Simon; Eva R Birnbaum; Robert W Atcher; Kevin D John; Olivier Rixe; Jeffrey P Norenberg
Journal:  Target Oncol       Date:  2018-04       Impact factor: 4.493

Review 4.  Cancer radioimmunotherapy with alpha-emitting nuclides.

Authors:  Olivier Couturier; Stéphane Supiot; Marie Degraef-Mougin; Alain Faivre-Chauvet; Thomas Carlier; Jean-François Chatal; François Davodeau; Michel Cherel
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-05       Impact factor: 9.236

5.  Influence of the linker on the biodistribution and catabolism of actinium-225 self-immolative tumor-targeted isotope generators.

Authors:  Christophe Antczak; Jaspreet S Jaggi; Clare V LeFave; Michael J Curcio; Michael R McDevitt; David A Scheinberg
Journal:  Bioconjug Chem       Date:  2006 Nov-Dec       Impact factor: 4.774

Review 6.  Realizing the potential of the Actinium-225 radionuclide generator in targeted alpha particle therapy applications.

Authors:  Matthias Miederer; David A Scheinberg; Michael R McDevitt
Journal:  Adv Drug Deliv Rev       Date:  2008-04-23       Impact factor: 15.470

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.